Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00842699 · ClinicalTrials.gov registry record
Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
A clinical trial of Renal Transplantation, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT00842699: Completed study of Renal Transplantation, sponsored by Brigham and Women's Hospital.
NCT00842699 is a study of Renal Transplantation that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 40 participants, below the 45-participant average among 7 other Renal Transplantation trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00842699, a study of Renal Transplantation, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.
Conditions Studied
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-03 |
What the finished NCT00842699 record still lists
NCT00842699 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 45-participant average among 7 other Renal Transplantation trials with a reported enrollment target (11% lower).
The record links to 1 condition, with Renal Transplantation appearing as the primary indexed condition, and to 0 interventions.
NCT00842699 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00842699 about?
NCT00842699 is a clinical study titled "Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab". The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.
What is the current status of trial NCT00842699?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2011-03.
What conditions does trial NCT00842699 study?
This clinical trial studies the following conditions: Renal Transplantation.
Who is sponsoring clinical trial NCT00842699?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00842699 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of TCD601 in de Novo Renal Transplant Recipients
ACTIVE NOT RECRUITING · Phase 2
-
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
Envarsus XR® in Adolescent Renal Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Tolerance by Engaging Antigen During Cellular Homeostasis
COMPLETED · Phase 1
-
A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection
COMPLETED · Phase 2
-
Study Evaluating Conversion From Tacrolimus to Sirolimus in Stable Kidney Transplant Recipients Receiving Myfortic
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia